194 related articles for article (PubMed ID: 31003160)
1. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
[TBL] [Abstract][Full Text] [Related]
2. Pixantrone beyond monotherapy: a review.
Barrenetxea Lekue C; Grasso Cicala S; Leppä S; Stauffer Larsen T; Herráez Rodríguez S; Alonso Caballero C; Jørgensen JM; Toldbod H; Leal Martínez I; D'Amore F
Ann Hematol; 2019 Sep; 98(9):2025-2033. PubMed ID: 31312929
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma.
Ikoma Y; Nakamura N; Kitagawa J; Miwa T; Takada E; Matsumoto T; Shibata Y; Nakamura H; Kanemura N; Kasahara S; Hara T; Sawada M; Tsurumi H; Shimizu M
Hematol Oncol; 2024 Jan; 42(1):e3236. PubMed ID: 37932900
[TBL] [Abstract][Full Text] [Related]
4. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Wu R; Ma L
Cell Transplant; 2023; 32():9636897231179364. PubMed ID: 37350429
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Budde LE; Wu D; Martin DB; Philip M; Shustov AR; Smith SD; Gooley TA; Chen TL; Libby EN; Chen EY; Kojouri K; Langerak A; Roden JE; Press OW; Gopal AK
Br J Haematol; 2018 Nov; 183(4):601-607. PubMed ID: 30596402
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
Pasvolsky O; Bassett RL; Ghanem S; Cuglievan B; Tewari P; Hosing C; Srour S; Ramdial J; Mahadeo KM; Khazal S; Petropoulos D; Popat U; Qazilbash M; Kebriaei P; Champlin R; Shpall EJ; Nieto Y
BMC Cancer; 2023 Dec; 23(1):1258. PubMed ID: 38124057
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
9. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
Fuji S; Kida S; Nakata K; Morishima T; Miyashiro I; Ishikawa J
Ann Hematol; 2021 Sep; 100(9):2253-2260. PubMed ID: 33169198
[TBL] [Abstract][Full Text] [Related]
10. Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
Plante MÉ; Feng X; Boudreault JS
Leuk Lymphoma; 2023; 64(7):1234-1242. PubMed ID: 37154396
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Chow VA; Rajendran JG; Fisher DR; Appelbaum FR; Cassaday RD; Martin PS; Holmberg LA; Gooley TA; Stevenson PA; Pagel JM; Green DJ; Press OW; Gopal AK
Am J Hematol; 2020 Jul; 95(7):775-783. PubMed ID: 32243637
[TBL] [Abstract][Full Text] [Related]
12. Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Aubrais R; Bouabdallah K; Chartier L; Herbaux C; Banos A; Brice P; Sibon D; Schiano JM; Cluzeau T; Laribi K; Le Calloch R; Bellal M; Delapierre B; Daguindau N; Amorim S; Agbetiafa K; Chauchet A; Besson C; Durot E; Bonnet C; Fouillet L; Bijou F; Tournilhac O; Gaulard P; Parrens MC; Damaj G
Blood Adv; 2023 Oct; 7(19):5733-5742. PubMed ID: 36477770
[TBL] [Abstract][Full Text] [Related]
13. [IEAC versus CEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for lymphoma: analysis of efficacy and safety in 106 cases].
Xiong Y; Chen J; Liu L; Luo X; Tang X; Wang X; Xiao Q; Zhang H; Wang L
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Dec; 40(12):1760-1767. PubMed ID: 33380399
[TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.
Nieto Y; Banerjee P; Kaur I; Kim KH; Fang D; Thall PF; Griffin L; Barnett M; Basar R; Hosing C; Ramdial J; Srour S; Daher M; Marin D; Jiang X; Chen K; Champlin R; Shpall EJ; Rezvani K
Transplant Cell Ther; 2024 Feb; 30(2):203.e1-203.e9. PubMed ID: 38042257
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.
Huang C; Tang TL; Qiu YY; Lin YP; Chen SL; Zhao RZ; Shi GQ; Liao SQ; Chen JH; Fu HY; Liu JZ; Xu BH; Liu TB; Yang Y
BMC Cancer; 2024 Jan; 24(1):72. PubMed ID: 38218811
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
Sandlund JT; Pui CH; Mahmoud H; Zhou Y; Lowe E; Kaste S; Kun LE; Krasin MJ; Onciu M; Behm FG; Ribeiro RC; Razzouk BI; Howard SC; Metzger ML; Hale GA; Rencher R; Graham K; Hudson MM
Ann Oncol; 2011 Feb; 22(2):468-71. PubMed ID: 20624787
[TBL] [Abstract][Full Text] [Related]
17. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience.
Rimner A; Lovie S; Hsu M; Chelius M; Zhang Z; Chau K; Moskowitz AJ; Matasar M; Moskowitz CH; Yahalom J
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1066-1076. PubMed ID: 28332991
[TBL] [Abstract][Full Text] [Related]
18. IVAC With or Without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas: Real-World Experience in the Modern Era.
Buege MJ; Dao PH; Drill E; LeVoir A; Pak T; Peterson TJ; Straus DJ
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):873-878. PubMed ID: 34413005
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics and Pharmacodynamics of Carfilzomib in Combination with Rituximab, Ifosfamide, Carboplatin, and Etoposide in Adult Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Lin LH; Ghasemi M; Burke SM; Mavis CK; Nichols JR; Torka P; Mager DE; Hernandez-Ilizaliturri FJ; Goey AKL
Target Oncol; 2023 Sep; 18(5):685-695. PubMed ID: 37632592
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.
Vardhana SA; Sauter CS; Matasar MJ; Zelenetz AD; Galasso N; Woo KM; Zhang Z; Moskowitz CH
Br J Haematol; 2017 Feb; 176(4):591-599. PubMed ID: 27982423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
